. The combination of ricin/TRAIL induces caspase activation. A549 lung epithelial cells were treated with 1 ng/mL ricin alone or in combination with 100 ng/mL TRAIL for 4 h at 37 °C followed by cell lysis and western blot and densitometry. The combination of ricin and TRAIL results in cleavage/activation of caspases (A) -3, (B) -7, (C) -8, and (D) -9. Results shown are the average from 3 independent experiments. Error bars = standard deviation. Figure S2 . Ricin/TNF-α and ricin/FasL do not induce caspase activation in A549 cells after 8 h. A549 lung epithelial cells were treated with 1 ng/mL ricin alone or in combination with 100 ng/mL TNF-α or FasL for 8 h at 37 °C followed by cell lysis and western blot. The combination of ricin/TNF-α or
. The combination of ricin/TRAIL induces caspase activation. A549 lung epithelial cells were treated with 1 ng/mL ricin alone or in combination with 100 ng/mL TRAIL for 4 h at 37 °C followed by cell lysis and western blot and densitometry. The combination of ricin and TRAIL results in cleavage/activation of caspases (A) -3, (B) -7, (C) -8, and (D) -9. Results shown are the average from 3 independent experiments. Error bars = standard deviation. Figure S2 . Ricin/TNF-α and ricin/FasL do not induce caspase activation in A549 cells after 8 h. A549 lung epithelial cells were treated with 1 ng/mL ricin alone or in combination with 100 ng/mL TNF-α or FasL for 8 h at 37 °C followed by cell lysis and western blot. The combination of ricin/TNF-α or ricin/FasL does not result in the cleavage/activation of caspases after 8 h. Shown are representative blots from 3 independent experiments. Figure S3 . The apoptotic stimuli CHX/TRAIL, CHX/TNF-α, and CHX/FasL induce caspase cleavage. A549 cells were treated with 250 ng/mL cycloheximide (CHX) combined with TNF-α, FasL, or TRAIL as a positive control for TRAIL-, TNF-, and FasL-induced apoptosis. Lysates were probed on western blot and densitometry was performed. As expected, when cycloheximide is combined with TNF-α, FasL, or TRAIL it results in the cleavage/activation of caspases (A) -3, (B) -6, (C) -7, (D) -8, and (E) -9. Results shown are the average from 3 independent experiments. Error bars = standard deviation. Figure S4 . Ricin/TRAIL induces caspase cleavage that is prevented by pharmacologic inhibitors. A549 lung epithelial cells were treated with 1 ng/mL ricin in combination with 100 ng/mL TRAIL in the absence or presence of caspase inhibitors for 4 h at 37 °C followed by cell lysis and western blot. Ricin/TRAIL induces cleavage/activation of caspases-3, -7, -8, and -9 which is prevented by (A,B) zDEVD-fmk (30 μM), (C) zIETD-fmk (30 μM), and (D) zLEHD-fmk (10 μM), respectively. Shown are representative blots from 3 independent experiments.
Figure S5. A549 cell death by ricin/TNF-α and ricin/FasL does not depend on caspases-6 or -9. A549 lung epithelial cells were treated with ricin alone or in combination with 100 ng/mL TNF-α in the presence or absence of caspase inhibitors for 24 h at 37 °C followed by measurement of cell death via WST-1 assay. Cell death induced by ricin/TNF-α or ricin/FasL was not affected by inhibition of (A,B) caspase-6 with zVEID-fmk (30 μM) or (C-D) caspase-9 with zLEHD-fmk (10 μM). Results shown are the average from 3 independent experiments. Error bars = standard deviation. Two-way ANOVA, *** p < 0.001. Figure S6 . The apoptotic stimuli CHX/TNF-α and CHX/FasL induce Bax-dependent cell death. A549 cells were treated with the combination of 250 ng/mL cycloheximide (CHX) and TNF-α or cycloheximide and FasL as positive controls for TNF-and FasL-induced apoptosis. As expected, (A) cycloheximide/TNF-α and (B) cycloheximide/FasL-induced apoptosis is prevented by Bax-inhibiting peptide v5 (100 μM). Results shown are the average from 3 independent experiments. Error bars = standard deviation. Two-way ANOVA, *** p < 0.001. Figure S7 . Cytochrome c is released into the cytoplasm of A549 cells treated with ricin/TRAIL but not those treated with ricin/TNF-α or ricin/FasL. A549 lung epithelial cells were treated with 1 ng/mL ricin alone or in combination with 100 ng/mL TRAIL, TNF-α, or FasL for 4 h at 37 °C followed by cytoplasmic extraction with digitonin and western blot. Cyt c is observed only in digitonin extracts from cells treated with ricin/TRAIL. Figure S8 . Cell death induced by ricin in combination with TNF-α or FasL does not depend on RIP1 kinase. A549 lung epithelial cells were treated with ricin alone or in combination with 100 ng/mL TNF-α or FasL in the presence or absence of the RIP1 inhibitior, necrostatin-1s (nec-1s, 50 μM), for 24 h at 37 °C followed by measurement of cell death via WST-1 assay. Cell death induced by the combination of ricin and (A) TNF-α or (B) FasL was not prevented by inhibition of RIP1. Results shown are the average from 3 independent experiments. Error bars = standard deviation. Two-way ANOVA, *** p < 0.001. Figure S9 . Mcl1 protein loss does not differ between ricin/TRAIL, ricin/TNF-α, and ricin/FasL. A549 lung epithelial cells were treated with 1 ng/mL ricin alone or in combination with 100 ng/mL TRAIL, TNF-α, or FasL for 4 or 8 h at 37 °C followed by cell lysis and western blot. Mcl1 degrades over 8 h of treatment but the pattern does not differ between ricin/TRAIL, ricin/TNF-α, and ricin/FasL. Shown are representative blots from 3 independent experiments. (50 μM), an inhibitor of calpains as well as cathepsins L and K, for 24 h at 37 °C followed by measurement of cell death via WST-1 assay. Cell death induced by the combination of ricin and (A) TNF-α or (B) FasL was not prevented by calpeptin. Results shown are the average from 3 independent experiments. Error bars = standard deviation. Two-way ANOVA, *** p < 0.001. Figure S11 . The cathepsin inhibitor, CATI-1, has no effect on A549 cell death by ricin/TRAIL. A549 lung epithelial cells were treated with ricin alone or in combination with 100 ng/mL TRAIL in the presence or absence of CATI-1 (20 μM) for 24 h at 37 °C followed by measurement of cell death via WST-1 assay. Cell death induced by the combination of ricin and TRAIL was not affected by inhibition of cathepsins. Results shown are the average from 3 independent experiments. Error bars = standard deviation. Figure S12 . Cell death induced by ricin/TNF-α or ricin/FasL is inhibited by N-acetylcysteine. A549 lung epithelial cells were treated with ricin alone or in combination with 100 ng/mL TNF-α or FasL for 24 h at 37 °C followed by measurement of cell death via WST-1 assay. Cell death induced by ricin/TNF-α and ricin/FasL was partially prevented by inhibition of (A,B) reactive oxygen species with N-acetylcysteine (NAC, 10 mM). Results shown are the average from 3 independent experiments. Error bars = standard deviation. Two-way ANOVA, *** p < 0.001. Figure S13 . Calu3 human lung epithelial cells are insensitive to cell death by ricin/TNF-α or ricin/FasL. Calu3 lung epithelial cells were treated with ricin alone or in combination with 100 ng/mL TRAIL, TNF-α, or FasL for 24 h at 37 °C followed by measurement of cell death via WST-1 assay. Cell death induced by ricin/TRAIL was significantly increased relative to ricin alone. Cell death by ricin/TNF-or ricin/FasL did not increase relative to ricin alone. Results shown are the average from 3 independent experiments. Error bars = standard deviation. Two-way ANOVA, *** p < 0.001. Figure S14 . Ricin/TRAIL induces caspase-dependent apoptosis while ricin/TNF-α and ricin/FasL induce cathepsin-dependent cell death in U937 human monocytes. U937 monocytes were treated with ricin alone or in combination with 100 ng/mL TRAIL, TNF-α, or FasL for 24 h at 37 °C followed by measurement of cell death via WST-1 assay. (A) Cell death induced by ricin/TRAIL was prevented by inhibition of caspase-3 with zDEVD-fmk (30 μM). Cell death by ricin/TNF-α and ricin/FasL was not affected by zDEVD-fmk. (B) Cell death by ricin/TNF-α and ricin/FasL was prevented by inhibition of cathepsins with CATI-1 (20 μM). Cell death by ricin/TRAIL was not affected by CATI-1. Results shown are the average from 3 independent experiments. Error bars = standard deviation. Two-way ANOVA, *** p < 0.001.
